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Abstract
The glucagon (GCG) peptide family consists of GCG, glucagon-like peptide 1 (GLP1), and GLP2, which are derived from a
common GCG precursor, and the glucose-dependent insulinotropic polypeptide (GIP). These peptides interact with cognate
receptors, GCGR, GLP1R, GLP2R, and GIPR, which belong to the secretin-like G protein-coupled receptor (GPCR) family. We
used bioinformatics to identify genes encoding a novel GCG-related peptide (GCRP) and its cognate receptor, GCRPR. The
GCRP and GCRPR genes were found in representative tetrapod taxa such as anole lizard, chicken, and Xenopus, and in
teleosts including medaka, fugu, tetraodon, and stickleback. However, they were not present in mammals and zebrafish.
Phylogenetic and genome synteny analyses showed that GCRP emerged through two rounds of whole genome duplication
(2R) during early vertebrate evolution. GCRPR appears to have arisen by local tandem gene duplications from a common
ancestor of GCRPR, GCGR, and GLP2R after 2R. Biochemical ligand-receptor interaction analyses revealed that GCRP had the
highest affinity for GCRPR in comparison to other GCGR family members. Stimulation of chicken, Xenopus, and medaka
GCRPRs activated Gas-mediated signaling. In contrast to chicken and Xenopus GCRPRs, medaka GCRPR also induced Gaq/11-
mediated signaling. Chimeric peptides and receptors showed that the K16M17K18 and G16Q17A18 motifs in GCRP and GLP1,
respectively, may at least in part contribute to specific recognition of their cognate receptors through interaction with the
receptor core domain. In conclusion, we present novel data demonstrating that GCRP and GCRPR evolved through gene/
genome duplications followed by specific modifications that conferred selective recognition to this ligand-receptor pair.
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Introduction
Glucagon (GCG) and GCG-like peptides exhibit a variety of
functions in the brain, gut, and endocrine tissues [1]. The GCG
gene encodes a large GCG precursor, which undergoes tissue-
specific posttranslational proteolytic processing to produce mature
GCG, glucagon-like peptide 1 (GLP1), and glucagon-like peptide 2
(GLP2) [2,3,4]. The mature form of GCG is released from the
pancreatic islets of Langerhans a cells in response to low blood
glucose level. Mature GCG enhances hepatic secretion of glucose
by increasing glycogenolysis and gluconeogenesis in the liver [5].
GLP1 and GLP2 are produced in the intestinal L-type endocrine
cells in response to food ingestion. GLP1 stimulates insulin
secretion from pancreatic b cells in a glucose-dependent manner
[6,7]. GLP2 is a nutrient-responsive growth factor that stimulates
specific trophic effects in the small and large intestines [8]. In the
brain GLP1 and GLP2 are produced predominantly in brainstem
neurons and transported to diverse regions of the central nervous
system, including the hypothalamus, thalamus, and cortex
[9,10,11]. GLP1 and GLP2 may increase satiety, leading to
reduced nutrient consumption and weight loss [12,13,14]. In
addition, GLP1 is neuroprotective and involved in neurite growth
and spatial learning ability [15,16]. The other GCC-related
peptide is glucose-dependent insulinotropic peptide (GIP), which is
encoded by the GIP gene. GIP is secreted from the K-cells of the
upper intestine, duodenum and jejunum [17]. GLP1 and GIP are
the main mammalian incretin hormones, accounting for approx-
imately 50–70% of the total insulin secretion from pancreatic b
cells [18]. In addition to its incretin effect, GIP has been
implicated in lipid metabolism and the development of obesity
via direct effects on adipose tissue. Further, GIP has been shown to
promote bone formation by stimulating osteoblast proliferation
and inhibiting apoptosis [19,20].
These peptides exert their actions through the class B (or
secretin-like) family of G protein-coupled receptors (GPCR)
[21,22]. Structural features of this family include a relatively long
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N-terminal extracellular domain (ECD), which contains an a-helix
followed by four b-strands that form two antiparallel sheets
[23,24]. Six conserved cysteine residues lock these secondary
structural elements together. In addition, an internal salt bridge
called the Sushi domain further stabilizes this core structure [25].
Because each class B GPCR contains this conserved fold in the
ECD, a common mechanism may underlie ligand recognition
[26,27,28,29]. Likewise, GCG family peptides share common
structural elements, such as a random coiled N-terminus followed
by an a-helix in the middle of each peptide [24,30]. Crystal
structures show that amino acids in the second half of the a-helix
of GCG peptides interact with the N-terminal ECD. In particular,
the hydrophobic face (Phe22, Ile/Val23, and Leu26) of the a-helix is
highly conserved amongst GCG peptide family members [28].
These hydrophobic residues are exposed to the complementary
hydrophobic binding pocket in the ECD [23,24]. In contrast, the
N-terminus and the first half of the a-helix of GCG peptides are
believed to interact with the core domain of their respective
receptors. The receptor core domain consists of 7 transmembrane
helices and extracellular loops [27]. However, the crystal structure
of the ligand-bound receptor core domain has not been reported.
Therefore, despite extensive biochemical studies
[31,32,33,34,35,36,37,38], the ligand-binding residues within the
core domain remain poorly defined. Recently, we reported that
the evolutionarily conserved amino acid residues His1 and Thr7 in
GLP1 and Ile196, Leu232, and Met233 in the core domain of
GLP1R mediate selective ligand-receptor interaction and receptor
activation [27,39].
Increased access to genomic sequencing data for many
vertebrate and invertebrate species and advances in bioinfor-
matics have allowed identification of genes encoding novel
peptides and GPCRs with BLAST search tools [40,41,42,43]. In
addition, synteny analyses and reconstruction of ancestral
genomes have enabled exploration into the origin and
relationship of peptide and receptor families [40,44]. These
analyses revealed that most peptide and receptor families
expanded through two rounds of whole genome duplication
(2R) and local duplications before and after 2R [40,41,42,45].
These duplication processes are followed by modification and/
or loss of genes. Ortholog-specific changes in the amino acid
sequences of peptides and receptors may discriminate against
interactions of a peptide with paralogs of the authentic receptor
and promote selective interactions between a peptide family and
its corresponding receptor family [27,28].
In the current study, we performed a BLAST search in
combination with genome comparison analysis and identified a
gene encoding a novel glucagon-related peptide (GCRP) and its
corresponding receptor (GCRPR) in various vertebrates. A
previous study referred to GCRP and GCRPR as exendin and
glucagon receptor-like receptor (GRLR), respectively [46].
However, our current phylogenetic and pharmacological studies
revealed that GCRP is independent from the exendin lineage
and has the highest affinity for GCRPR. Thus, we propose
changing the names of the peptide and receptor to GCRP and
GCRPR, respectively. We present an evolutionary history of
GCRP and GCRPR based on phylogenetic and synteny
analyses. In addition, we demonstrate the pharmacological
properties of this ligand-receptor pair by performing ligand-
binding, receptor activation, and signaling assays in a heterol-
ogous expression system. Finally, we identified amino acid
residues within peptides that mediated selective interaction with
their chimeric receptors.
Results
Presence of a Novel GCRP
A genome BLAST search identified genomic fragments
containing novel GCRP sequences in a variety of vertebrates,
including chicken, anole lizard, Xenopus tropicalis, medaka, fugu,
stickleback, and tetraodon but not in human, mouse, and
zebrafish. Full-length cDNA sequences were available for the
GCRP precursors in chicken and Xenopus [46]. However, only
genome fragments having GCRP were identified for other species
in our study. The predicted GCRP mature peptide sequence was
distinct, while it retained a high degree of identity with GCG,
GLP1, GLP2, and GIP. For example, the conserved KM/IK
motif at positions 16, 17 and 18 was unique to GCRP, whereas
other residues in GCRP are very similar to those found in this
peptide family (Fig. 1A). A previous study by Irwin and Prentice
[46] suggested that GCRP has a close relationship with exendin-4,
which was originally discovered in the Gila monster (Heloderma
suspectum) [47]. However, our phylogenetic study suggested that the
amino acid sequences of exendin-4 and -3 were more similar to
GLP1 than GCRP. In addition, exendin-1 and -2 have close
relationships with VIP and PACAP. Thus, it seems likely that this
novel GCRP belongs to a lineage independent of exendin or its
related peptides.
Genome synteny analyses for GCRP-containing genomic frag-
ments were described in our previous article [40]. GCRP was
located near phosphodiesterase 1B (PDE1B), homeobox C13
(HOXC13), v-erb-b2 erythroblastic leukemia viral oncogene
homolog 3 (ERBB3), insulin-like growth factor binding protein 6
(IGFBP6), myosin light chain 6B (MYL6B), and complement
component 1 q subcomponent-like 4 (C1QL6) genes (Fig. S1A).
However, the GCRP gene was not located on the human and
zebrafish chromosomes that harbor these neighboring genes.
There appear to be two forms of GCRP in chickens. One is located
at 62 megabases of Un_random (UR), and the other is located at 1
megabase of the E22C19W28 fragment. These two genes may
have emerged by a local tandem duplication, because GCRP
neighbors in chicken E22C19W28 including aquaporin 2 (AQP2),
Fas apoptotic inhibitory molecule 2 (FAIM2), and solute carrier
family 4 sodium bicarbonate cotransporter member 8 (SLC4A8)
were localized to GCRP-containing chromosomes in other
vertebrates (Fig. S1A). Teleost-specific genome duplication may
not have contributed to evolution of the second form of GCRP.
GCRP may have emerged through two rounds of whole genome
duplication, as the paralogs for GCRP and its neighbors were found
to be aligned in three different paralogous chromosomal regions
(Fig. S1B). Further details are provided in Information S1.
Presence of a Novel GCRPR
A genome BLAST search identified novel receptor sequences
similar to those of GIPR, GCGR, GLP1R, and GLP2R in the
genomes of chicken, anole lizard, Xenopus tropicalis, medaka,
stickleback, tetraodon, and fugu. We named these sequences
GCRPR. Thus, species that express GCRP also express the
corresponding receptor. Phylogenetic analysis of GCRPR with its
related receptors revealed that GCRPR has the closest relationship
with GIPR (Fig. 2). The medaka and fugu GIPRs reported in a
previous study [48] were redefined to be GCRPR in this study.
The confusion in nomenclature for medaka and fugu GCRPRs is
likely due to a phylogenetically close relationship between
GCRPR and GIPR. Our phylogenetic and synteny analyses did
not find GIP orthologs for medaka and fugu, whereas this species
contained GCRP orthologs (Fig. 1 and Fig. S1). Interestingly,
zebrafish contained both GIP and GIPR but lacked GCRP and
Novel Glucagon-Related Peptide and Its Receptor
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GCRPR. These results indicate species-specific coevolution of the
GCRP-GCRPR pair.
We previously described genome synteny analyses for GCRPR-
containing genomic fragments [40]. Synteny analyses for genomic
fragments containing GCRPR and its related receptors are very
complicated. Thus, a detailed description is provided in Informa-
tion S1. Briefly, our study showed that GCRPR clustered with
GCGR and GLP2R on the same chromosome in many vertebrates,
suggesting that these genes have arisen through local duplications
after 2R. In contrast, GLP1R and GIPR were located on different
chromosomes (Fig. S2). Neighbor gene analyses revealed that
ohnologs (or paralogs) of GCRPR/GLP2R/GCGR neighbors, such
as glutamate receptor ionotropic N-methyl D-aspartate 2C
(GRIN2C), protein phosphatase 1 regulatory subunit 27 (PPP1R27),
sirtuin 7 (SIRT7), peripheral myelin protein 22 (PMP22), lectin
galactoside-binding soluble 9C (LGALS9C), and FAM83E were
found on GIPR-containing genome fragments, suggesting that
GCRPR/GLP2R/GCGR- and GIPR-containing genome fragments
were generated by 2R. In addition, ohnologs (or paralogs) of GIPR
neighbor genes DEAH box polypeptide 34 (DHX34), potassium
channel subfamily K member 6 (KCNK6), and nuclear factor of
kappa light polypeptide gene enhancer in B-cells inhibitor beta
(NFKBIB) were observed in GLP1R-containing genome fragments
(Fig. S2). This observation raises the possibility that one
chromosome fragment harboring GCRPR/GLP2R/GCGR and
GLP1R split into two chromosomal fragments before 2R. Thus,
GCRPR appears to have emerged through local duplication of an
ancestral gene of GCRPR, GLP2R, GCGR, and possibly GLP1R.
However, further investigation is needed.
GCRPs Activate GCRPRs with a Higher Potency than
Related Peptides
To identify authentic ligands for GCRPR, we cloned GCRPR
cDNAs from chicken (ch), Xenopus (xe), and medaka (md). Each
GCRPR-expressing plasmid was co-transfected into HEK293T
cells with the pCRE-luc reporter gene to examine Gas-mediated
signal activation [49]. Cells were then treated with increasing
concentrations of various peptide forms, including GCRP, GIP,
GLP1, GLP2, GCG, and exendin-4 (Table 1). GCRP from each
species induced a concentration-dependent increase in luciferase
activity with the highest potency toward its cognate receptor
(EC50:0.87 nM chGCRP, 2.24 nM xeGCRP, and 6.76 nM
mdGCRP). Related peptides exhibited relatively low potencies
toward GCRPR (Table 2 and Figs. 3A, B, and C). It is of
particular interest to note that the potency of exendin-4 at
chGCRPR and xeGCRPR was clearly lower than GCRP,
Figure 1. Amino acid sequence alignment of GCRP and neighbor-joining phylogenetic tree for related peptides of vertebrates. A,
The mature peptide sequences of GCRP were predicted and aligned along with the GIP, GCG, GLP1, GLP2, and Gila monster exendins. Conserved
residues for GCRPs and related peptides are indicated by different colors as proposed by the ClustalX-2.1 program. The GCRP-specific motif at
positions 16–18 is highlighted by red dots above the sequences. B, Neighbor-joining phylogenetic tree for GCRP-related peptides of human (hu),
mouse (mo), chicken (ch), anole lizard (an), Xenopus (xe), zebrafish (zf), medaka (md), fugu (fu), stickleback (sb), and tetraodon (to) along with Gila
monster exendins and human SCT, GHRH, VIP, and PACAP. The mature peptide sequences were aligned on ClustalX-2.1, and a tree was constructed
with MEGA 5.05. Bootstrap numbers represent 1,000 replicates.
doi:10.1371/journal.pone.0065420.g001
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whereas the potency at mdGCRPR was very similar to that of
mdGCRP (Fig. 3C).
Although GCRPs exhibit a high degree of sequence similarity
with one another, there are some variations in amino acid
sequences. These differences might cause species-specific activity
of GCRP toward GCRPR. GCRPs from chicken, Xenopus, and
medaka were added to cells expressing GCRPR from different
species (Table 2 and Figs. 3D, E, and F). Chicken and Xenopus
GCRPs revealed similarly high potencies for chGCRPR and
xeGCRPR, whereas mdGCRP exhibited significantly lower
potencies for these receptors. All three peptides showed similar
potencies toward mdGCRPR (Fig. 3F). The low potency of
mdGCRP toward chGCRPR and xeGCRPR may be due to
variations in the amino acid sequences, particularly at positions 3,
5, 12, 21, and 24.
We then examined whether GCRP can activate other GCRPR-
related receptors such as GLP1R, GCGR, and GIPR in chicken,
Xenopus, and medaka. The results revealed that GCRP barely
activated the GCRPR-related receptors in these species (data not
shown). Together, these results suggest that GCRP is likely an
Figure 2. Neighbor-joining phylogenetic tree for GCRPR-related receptors. Human (hu), mouse (mo), chicken (ch), anole lizard (an), Xenopus
(xe), zebrafish (zf), medaka (md), fugu (fu), stickleback (sb), and tetraodon (to) along with human SCTR, GHRHR, VIPRs, and ADCYAP1R1 were
examined. The amino acid sequences were aligned on ClustalX-2.1, and a tree was constructed with MEGA 5.05. Bootstrap numbers represent 1,000
replicates.
doi:10.1371/journal.pone.0065420.g002
Novel Glucagon-Related Peptide and Its Receptor
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Figure 3. Activities of GCG family peptides on GCRP receptor. HEK293T cells were co-transfected with CRE-luc and plasmids containing
chGCRPR (A), xeGCRPR (B), or mdGCRPR (C) in 48-well plates. Forty-eight hours after transfection, cells were treated with the indicated concentrations
of peptides (& for GCRP; N for chGIP; e for chGLP2;# for chGCG; g for huGLP1; . for Exe-4). Species-specific responses of chGCRPR (D), xeGCRPR
(E), and mdGCRPR (F) were determined by treating cells with increasing concentrations of GCRP (. for chGCRP; ? for xeGCRP;N for mdGCRP) for 6 h,
and luciferase activity was examined.
doi:10.1371/journal.pone.0065420.g003
Table 1. Amino acid sequences for GCRPs and related peptides.
Peptides 1 11 21 31 41
Chicken GCRP HSEGTFTSDF TRYLDKMKAK DFVHWLINT
Xenopus GCRP HSEGTFSSDL TRYLDKMKAK DFVQWLMN
Medaka GCRP HTDGMFTSDL TNYLDKMKAK NFVEWLAAIK QQE
Human GLP1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR
Chicken GLP1 HAEGTYTSDI TSYLEGQAAK EFIAWLVNGRa
Medaka GLP1 HADGTFTSDV SAYLKEQAIK DFVAKLKSGQ I
Human GLP2 HADGSFSDEM NTILDNLAAR DFINWLIQTK ITD
Chicken GLP2 HADGTFTSDI NKILDDMAAK EFLKWLINTK VTQ
Medaka GLP2 HVDGSFTSDV NKVLDSMAAK EYLLWVMTSK PSNE
Human GIP YAEGTFISDY SIAMDKIHQQ DFVNWLLAQK GKKNDWKHNI TQ
Chicken GIP YSEATLASDY SRTMDNMLKK NFVEWLLARR EKKSDNVIEP Y
Human GCG HSQGTFTSDY SKYLDSRRAQ DFVQWLMNT
Chicken GCG HSQGTFTSDY SKYLDSRRAQ DFVQWLMST
Medaka GCG1 HSEGTFSNDY SKYLEDRKAQ DFVRWLMNN
Medaka GCG2 HSEGTFSNDY SKYLETRRAH DFVQWLKNS
Exe-4 HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPSG
Chicken [GQA]GCRP HSEGTFTSDF TRYLDGQAAK DFVHWLINT
Chicken [KMK]GLP1 HAEGTFTSDV SSYLEKMKAK EFIAWLVKGR
doi:10.1371/journal.pone.0065420.t001
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authentic ligand for GCRPR at least in terms of their pharma-
cological properties.
Human Receptors for Glucagon Family Peptides Respond
Weakly to GCRPs
Exendin-4 exhibited a very strong potency toward mammalian
GLP1R. Thus, we examined the potency of GCRP to human
GLP1R, GCGR, GLP2R, and GIPR in comparison with exendin-
4. HEK293T cells transfected with human GIPR, GLP1R, GLP2R,
or GCGR were treated with GCRPs from three different species,
exendin-4, and their corresponding ligand forms (Table 1). All
receptors were activated by their cognate ligands with the highest
potencies. Exendin-4 fully activated huGLP1R with a potency
similar to GLP1 (EC50<0.1 nM) and activated huGIPR and
huGLP2R with moderate potency (EC50<0.1 mM) but not
huGCGR. In contrast to exendin-4, GCRPs activated huGLP1R,
huGLP2R, and huGCGR only at high concentrations. GCRPs
marginally activated huGIPR even at 10 mM. (Table 3 and Fig. 4).
This result suggests that GCRPs exhibit pharmacological activity
distinct from that of exendin-4.
Receptor-binding Affinity of GCRP
To confirm the binding affinities of GCRPs to their receptors,
we adopted a competitive displacement binding assay. Because
chGCRP exhibited high potencies toward ch-, xe-, and
mdGCRPR in the reporter assay system (Fig. 3), we labeled
chGCRP with 125I. HEK293T cells transfected with each GCRPR
were incubated with 125I-chGCRP in the absence or presence of
increasing concentrations of various unlabeled cold peptides. A
displacement binding assay revealed that each GCRP had the
highest binding affinity for its cognate receptor, which is consistent
with the results obtained from the reporter assay (Fig. 3). The IC50
values were 43.65 nM for chGCRP, 63 nM for xeGCRP, and
0.32 mM for mdGCRP (Table 4 and Fig. 5). Exendin-4 exhibited
relatively higher affinity for chGCRPR and xeGCRPR in
comparison to related peptides. Interestingly, the affinity of
exendin-4 for mdGCRPR is similar to that of mdGCRP,
indicating that exendin-4 retains the ability to bind and activate
mdGCRPR (Fig. 5).
Intracellular GCRPR Signaling
Upon ligand binding, GCGR family receptors induce Gas-
mediated adenylyl cyclase activity and increase intracellular cAMP
production [6,50]. Thus, we hypothesize that GCRPRs may also
stimulate this pathway to generate cAMP. Indeed, our reporter
assay demonstrated that activation of GCRPR induced cAMP
responsive element (CRE)-driven reporter activity (Fig. 3). To
further confirm the intracellular signaling pathway of GCRPRs,
we measured cAMP levels by real-time luminescence in cells
expressing Glosensor-22F cAMP, which interacts directly with cAMP
[51]. As shown in Fig. 6A, GCRPs increase cAMP levels by
stimulating their cognate receptors with high potencies (EC50,
chGCRP: 5.8 nM; xeGCRP: 46 nM; mdGCRP: 1.15 nM),
suggesting that GCRPR activates the Gas–mediated signaling
pathway (Fig. 6A). Because some GCGR family members
stimulate intracellular calcium accumulation in a certain condition
[52], it can be postulated that GCRPR activates the Gaq/11-PLCb
pathway. Thus, we measured GCRP-induced accumulation of
inositol phosphates (IP) in HEK293T cells transfected with the
GCRPR genes. The mdGCRP induced IP production through its
cognate receptor, whereas neither chGCRPR nor xeGCRPR were
able to increase IP levels (Fig. 6B). The ability of mdGCRPR to
stimulate Gaq/11-mediated signaling was further determined with
a SRE-luc reporter assay system [43,49,53]. The SRE-luc reporter
assay revealed that only mdGCRPR but not ch- and xe-GCRPR
stimulated SRE-driven transcription activity (Fig. 6C). These data
suggest that mdGCRPR acquired the ability to activate Gaq/11-
mediated signaling in addition to Gas-mediated signaling.
Alternatively, chGCRPR and xeGCRPR may have evolutionarily
lost the ability to stimulate Gaq/11-mediated signaling.
Partial Identification of the Motif Conferring Ligand
Specificity toward GCRPR
Although GCG family peptide sequences are relatively similar,
each specifically activates its cognate receptor with a sub-
Table 2. Ligand potency (EC50 value) and efficacy (Emax value) for GCRPR.
chGCRPR xeGCRPR mdGCRPR
peptides EC50 Emax EC50 Emax EC50 Emax
[nM] [fold induction] [nM] [fold induction] [nM] [fold induction]
chGCRP 0.8760.13 6.0060.09 5.8661.11 30.0960.72 33.7364.64 8.1260.17
xeGCRP 1.1860.46 6.2560.23 2.2460.30 30.4360.49 30.6266.93 8.1060.27
mdGCRP 68.23617.28 6.9360.22 94.62612.87 31.9660.75 6.8461.07 7.9060.16
Exe-4 14.4562.63 6.0060.15 26.2463.11 31.5260.56 9.0666.66 8.0460.20
chGIP 69.18610.66 6.2260.16 274.16662.20 32.3561.53 ND ND
huGLP1 119.95627.06 6.2460.25 390.84669.39 35.0061.39 ND ND
chGLP2 33.4267.06 6.2660.19 ND ND ND ND
mdGLP1 ND ND ND ND NR NR
mdGLP2 ND ND ND ND NR NR
huGCG 35.3267.95 6.3060.21 49.4368.38 32.7360.96 ND ND
mdGCG1 ND ND ND ND 107.89633.20 4.2660.19
mdGCG2 ND ND ND ND NR NR
Results are presented as mean 6 S.E. of at least three independent experiments. NR, no response; ND, not determined.
doi:10.1371/journal.pone.0065420.t002
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Figure 4. GCRP activities toward the human GCGR family. Plasmids containing huGIPR (A), huGLP1R (B), huGLP2R (C), or huGCGR (D) cDNA
were co-transfected with the CRE-luc reporter vector into HEK293T cells. Forty-eight hours after transfection, cells were treated with various
concentrations of human peptides (N for huGIP, huGLP1, huGLP2, and huGCG), GCRP (. for chGCRP; m for xeGCRP; e for mdGCRP), and Exe-4 (%)
for 6 h. Luciferase activity was then determined.
doi:10.1371/journal.pone.0065420.g004
Table 3. Ligand potency (EC50 value) and efficacy (Emax value) for the human GCGR family.
huGIPR huGLP1R huGLP2R huGCGR
peptides EC50 Emax EC50 Emax EC50 Emax EC50 Emax
[nM]
[fold
induction] [nM]
[fold
induction] [nM]
[fold
induction] [nM]
[fold
induction]
Exe-4 22.8665.61 5.3660.15 0.0960.03 40.9561.51 107.15631.35 6.2960.28 NR NR
chGCRP NR 3.0362.41 48.8769.15 19.8460.57 591.566126.74 6.3260.24 42.66614.47 6.3260.24
xeGCRP NR 1.9560.14 .1000 24.1161.68 NR NR 181.55639.49 2.0960.12
mdGCRP NR 2.1160.09 155.96632.84 20.9060.74 NR NR 175.39641.78 2.2760.11
huGIP 0.1760.05 5.2160.12 ND ND ND ND ND ND
huGLP1 ND ND 0.1460.03 40.6160.73 ND ND ND ND
huGLP2 ND ND ND ND 0.8960.25 6.0960.09 ND ND
huGCG ND ND ND ND ND ND 0.7860.21 6.0960.18
Results are presented as mean 6 S.E. of at least three independent experiments. NR, no response; ND, not determined.
doi:10.1371/journal.pone.0065420.t003
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nanomolar EC50 value in most cases. This implies that a unique
motif in each peptide mediates interaction with the receptor. To
identify GCRP-specific amino acids, we compared its sequence
with other GCG family members. We found that residues at
positions 16–18 exhibited peptide-specific modifications such that
the K16M/I17K18, S/T16R17R18, and G/D16Q17A18 motifs were
conserved in GCRP, GCG, and GLP1, respectively. This
observation raises the possibility that the K16M/I17K18 motif in
GCRP allows the peptide to distinguish GCRPR from other GCG
family receptors. To examine the effect of this region on receptor
activation, we made mutant peptides of chicken GCRP and GLP1
in which the regions with G16Q17A18 and K16M17K18 were
swapped. We compared the activities of each mutant peptide on
each receptor. Wild-type GCRP and [G16Q17A18]GCRP activat-
ed chGCRPR with similar potency. However, [K16M17K18]GLP1
was significantly more potent toward chGCRPR than wild-type
GLP1 but similar to GCRP (Table 5 and Fig. 7A). Similarly,
GLP1 and [K16M17K18]GLP1 activated chGLP1R with similar
potencies and efficacies, whereas [G16Q17A18]GCRP was more
potent than GCRP (Table 5 and Fig. 7B). Thus, replacement of
K16M17K18 in GLP1 and G16Q17A18 in GCRP greatly enhanced
potency toward GCRPR and GLP1R, respectively, indicating that
these residues are potentially important for determining receptor
specificity. However, swapping motifs did not significantly change
the potencies and efficacies of peptides toward their cognate
receptors, suggesting that other regions in these peptides may
compensate for the role of the mutated residues.
Biochemical data and structural analysis of the ligand-bound
ECD of the receptor suggested that the N-termini of GCG
peptides bind to core regions of the receptors, whereas the second
half of the a-helix of the peptide interacts with the ECD of the
receptor. Interestingly, G16Q17A18 in GLP1 and K16M17K18 in
GCRP reside at the border between regions that interact with the
core domain and ECD. To explore the regions of the receptor that
interact with K16M17K18 or G16Q17A18, we designed a chimeric
receptor containing the N-terminal ECD of GCRPR and the core
domain of GLP1R (GCRPR/GLP1R) (Figs. 7 C and D). GLP1
and [K16M17K18]GLP1 exhibited higher potencies and efficacies
than GCRP toward the chimeric receptors. Interestingly, intro-
ducing G16Q17A18 into GCRP significantly increased potency but
not efficacy toward the chimeric receptors (Table 5 and Figs. 7 C
and D). The potencies and efficacies of the peptides toward
chimeric receptors containing the core domain of GLP1R are
similar to those toward wild-type GLP1R. Thus, it can be
postulated that the K16M17K18 and G16Q17A18 motifs are likely to
interact with the core domain of the receptor. We have
constructed chimeric receptors containing the GCRPR core
domain with human or chicken GLP1R ECDs. However, all
these constructs responded very poorly to the ligands including
GLP1, GCRP, and chimeric peptides (Data not shown). Probably,
these combinations of the GLP1R ECD and the GCRPR core
domain may induce unexpected conformation which does not
allow either ligand binding or receptor activation.
Discussion
The GCG-related peptide and receptor family is one of the best-
studied ligand and receptor families, particularly in gut-brain
interaction systems. In the current study, we used bioinformatics to
identify GCRP and GCRPR, which are novel members of this
ligand-receptor family. These new members are present in a
variety of tetrapods and teleost but not in mammals and zebrafish.
Genome synteny and phylogenetic analyses revealed that GCRP is
likely to have emerged through 2R. Thus, GCRP, GCG, and GIP
are ohnologous to one another. Two GCRP genes in chicken may
have evolved through local duplication following 2R during the
emergence of birds. In contrast, the evolutionary history of
GCRPR is more complex. Genome synteny analyses suggested
that GCRPR, GCGR, GLP2R, and GLP1R were on a common
genome fragment that was a paralogon of GIPR-containing
genome fragments. This observation indicates that GCRPR,
GCGR, GLP2R, and GLP1R have emerged through local
duplication following 2R before the divergence of tetrapods and
teleosts [40]. According to our phylogenetic and synteny analyses,
many teleost species with the exception of zebrafish have retained
Figure 5. Ligand-binding affinity of GCRP receptors. A cell-binding assay was performed in HEK293T cells expressing chGCRPR (A), xeGCRPR
(B), or mdGCRPR (C) with 125I-chGCRP in the presence of various concentrations of cold ligand (% for GCRP;m for chGLP1;N for huGCG;h for Exe-4).
doi:10.1371/journal.pone.0065420.g005
Table 4. Ligand affinity (IC50) toward GCRPRs.
IC50 [nM]
peptides chGCRPR xeGCRPR mdGCRPR
GCRP 43.55611.11 65.53620.44 327.34651.02
chGLP1 .1000 .1000 ND
huGCG .1000 .1000 ND
Exe-4 217.77693.19 374.11684.88 337.29642.82
Results are presented as mean 6 S.E. of at least three independent
experiments. ND, not determined.
doi:10.1371/journal.pone.0065420.t004
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GCRPR but lost GIPR. Similarly, teleost species that express GCRP
do not have the gene encoding the GIP peptide. Thus, with the
exception of zebrafish, teleost species may have lost the GIP and
GIPR system following 2R before the divergence of teleost and
tetrapods.
Prior to our study, GCRP was classified as a member of the
exendin-4 family [46]. However, our phylogenetic study revealed
that GCRP is more closely related to GIP versus other peptide
members, whereas exendin-4 is more similar to GLP1 with respect
to its amino acid sequence. In addition, GCRP has biochemical
properties distinct from those of exendin-4, GCG, GLP1, GLP2,
and GIP. Chicken, Xenopus, and medaka GCRPs exhibited the
highest potencies and affinities toward their corresponding
GCRPRs but showed very low potencies to human GIPR,
GLP1R, GLP2R, and GCGR. Interestingly, exendin-4 showed a
similar potency and affinity for medaka GCRPR as medaka
GCRP but much greater potency for human GLP1R than medaka
GCRP. This unexpected result may be due to the promiscuous
activity of exendin-4. Indeed, exendin-4 can fully activate GLP1R
and moderately activates GIPR, GLP2R, and GCRPR. Our
biochemical observations clearly indicate that GCRP is a
functional ligand for GCRPR.
Most mammalian GCGR family members are coupled primar-
ily to the Gas-mediated signaling pathway [5]. Although signaling
downstream of non-mammalian GCGR is not fully determined,
this receptor family is considered to be coupled to Gas. Some
family members can induce calcium accumulation and other
signaling pathways [52]. However, these responses may be
secondary effects related to increased intracellular cAMP [54].
Similarly, GCRPR is coupled primarily to Gas, as demonstrated
by increased cAMP levels and CRE-luc reporter activity in
response to GCRP stimulation. Interestingly, medaka GCRPR but
not Xenopus or chicken GCRPR activated Gaq/11-mediated
signaling. Stimulation of medaka GCRPR increased cytoplasmic
IP levels and SRE-luc reporter activity. Thus, receptor coupling to
both the Gas and the Gaq/11 pathways is a unique characteristic of
medaka GCRPR. However, the physiological relevance of this
dual coupling remains to be investigated.
Duplicated paralogs of peptides and receptors have undergone
sequence modifications during evolution, leading to diversification
and specification of ligand-receptor pairs. Specific diversification
of peptides, in other words, conservation within orthologs but
variation among paralogs could confer selective interaction of a
peptide with the cognate receptor, allowing discrimination of
paralogous receptors [27,55,56,57]. Consistent with this hypoth-
esis, we observed that the K16M/I17K18 motif in GCRP is
conserved amongst vertebrates but shows variation from the
corresponding residues in other peptides. These positions are
relatively conserved for GCG (S/T16R17R18) and GLP1 (G/
D16Q17A18), indicating that the motif at positions 16–18 contrib-
utes to selective interaction with the cognate receptor. Indeed,
chimeric [K16M17K18]GLP1 exhibited increased potency toward
chGCRPR compared to wild-type chicken GLP1. Chimeric
[G16Q17A18]GCRP was more potent for chGLP1R than wild-
type chicken GCRP, suggesting that these motifs, at least in part,
contribute to selective recognition of their cognate receptors.
However, it is unclear why GCRP with G16Q17A18 and GLP1
with K16M17K18 retained wild-type-like potencies to GCRPR and
GLP1R, respectively. It is likely that modification of these residues
can be structurally compensated, allowing high potency to the
corresponding receptors to be retained.
In contrast to the motif at positions 16–18, GCRP exhibited
high conservation of residues that are known to be important for
receptor interaction. For example, residues Ala19, Lys20, Phe22,
Ile23, Leu26, and Val27 in the a-helix of GLP1 directly contact the
ECD of GLP1R [24]. Ala19, Lys20, Phe22, and Leu26 are identical
to residues in the corresponding positions of GCRP. Further, Ile23
and Val27 are replaced by Val23 and Ile27 in GCRP, which have
similar biochemical properties to Ile23 and Val27, respectively.
His1, Gly4, Phe6, Thr7, and Asp9 of GLP1 are critical for
maintaining the secondary structure and for mediating interaction
with the receptor [27,31,34]. These residues in GLP1 are identical
to those of GCRP, which may confer cross-reactivity of these
peptides with related receptors. Further, this similarity may lead to
high and full potency of [G16Q17A18]GCRP toward GLP1R and
chimeric GCRPR/GLP1R, respectively.
The residues in the receptor core domain and ECD that
mediate interaction with the K16M17K18/G16Q17A18 motif of
peptides remain unknown. The crystal structure of the GLP1-
bound ECD of GLP1R demonstrated that amino acid residues
between Ala18 and Val27 of the peptide bind to the ECD of the
receptor [24]. Similarly, other crystal structures of ligand-bound
Figure 6. GCRPR-mediated signaling pathway. cAMP accumulation (A) or IP production (B) in response to various concentrations of GCRP was
determined in HEK293T cells transfected with plasmids containing GCRP receptors (N for chGCRPR; . for xeGCRPR; e for mdGCRPR). mdGCRP
induces SRE-luc activity through mdGCRPR (C). Forty-eight hours after transfection with the receptor and the reporter genes, HEK293T cells were
treated with different concentrations of GCRPs for 6 h. Luciferase activity was determined.
doi:10.1371/journal.pone.0065420.g006
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ECDs suggested that residues starting from position 18 or 19
interact with the ECD of the receptor [28]. Thus, motifs at
positions 16–18 of the peptides are at the border between residues
that interact with the ECD and residues that contact the core
domain. Particularly, Gly16 of GLP1 is involved in the formation
of a kink in the peptide a-helix [24]. Our study showed that the
GLP1R and GCRPR/GLP1R chimeric receptor, both of which
contain the GLP1R core domain, responded better to GLP1 than
GCRP. Further, [G16Q17A18]GCPR increased potency to this
chimeric receptor up to that of wild-type GLP1, indicating that the
G16Q17A18 motif may contact the core domain of the chimeric
receptor. Thus, the K16M17K18/G16Q17A18 motif in the peptide
may interact with residues in the core domain of the receptor.
In conclusion, our discovery of GCRP and its receptor demon-
strates the evolutionary history of GCG-related peptides and their
receptors in vertebrates. Duplication of the ancestral genes encoding
thesepeptide and receptor families followedby specificmodifications
in the amino acid sequences of GCG family peptides and receptors
contributes to selective interaction of a ligand with its corresponding
receptor. Further identification of specific residues inGCRP,GLP1,
and their receptors is particularly important for determining the
structure of ligand binding pocket in the receptor. This information
will facilitate the development of potent agonists and antagonists of
GCGR family members, which are involved in a variety of
pathophysiological processes.
Materials and Methods
Data Retrieval and Phylogenetic Analysis of GCG Family
Peptides and Receptors
The amino acid sequences of GCG-like family peptides and
receptors were downloaded from either the Ensembl Genome
Browser (http://www.ensembl.org) or the GenBank database with
the Entrez data retrieval tool (http://www.ncbi.nlm.nih.gov/
Entrez/). Specifically, search tools provided by Ensembl Genome
Browser for orthologous or paralogous genes identified genes from
non-mammalian vertebrates. This data set was the start set. Genes
that were not part of the start set were manually searched against
Figure 7. Potencies and efficacies of chimeric GCRP/GLP1 peptides toward chimeric GCRPR/GLP1R. Plasmids containing wild-type
chGCRPR (A), chGLP1R (B), chimeric chGCRPR/chGLP1R (C), or chimeric chGCRPR/huGLP1R (D) cDNAs were introduced into HEK293T cells with the
CRE-luc plasmid. Luciferase activities stimulated by graded concentrations of chGCRP (%), chGLP1 (m), ch[GQA]GCRP (N), or ch[KMK]GLP1 (e) were
determined.
doi:10.1371/journal.pone.0065420.g007
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the human, mouse, chicken, anole lizard, Xenopus tropicalis,
zebrafish, medaka, fugu, stickleback, and tetraodon genome
databases with the TBLASTN algorithm. Putative signal peptides
were predicted by SignalP 3.0 (http://www.cbs.dtu.dk/services/
SignalP/). The full set of GCG-like peptide and receptor
sequences were aligned on the Windows version of ClustalX-2.1
(Gonnet matrix, gap opening penalty 10, and gap extension 0.2).
Alignments were bootstrapped 1000 times, and neighbor-joining
trees were obtained using MEGA 5.05.
Chemicals and Hormones
All chemicals were obtained from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise stated. Restriction enzymes were
obtained from New England Biolabs (Ipswich, MA, USA). Wild-
type human (hu) GIP, huGLP1, huGLP2, huGCG, chicken (ch)
GCRP, chGLP1, chGIP, chGLP2, Xenopus (xe) GCRP, medaka
(md) GCRP, mdGLP1, mdGLP2, mdGCG1, mdGCG2, chimeric
[KMK]GLP1, and chimeric [GQA]GCRP were synthesized by
AnyGen (Gwangju, Korea). All peptide sequences are listed in
Table 1. The purities of the synthesized peptides were greater than
98% according to high-performance liquid chromatography. All
peptides were dissolved in DMSO and then diluted in media to the
desired working concentrations.
RNA Isolation and Reverse Transcriptase-polymerase
Chain Reaction (RT-PCR)
Brain, liver, and pancreatic tissues collected from White
Leghorn hen were provided by Biopoa Co Ltd. (Suwon, Korea).
Animal procedures were approved by the institutional animal care
and use committee (IACUC) of the Biopoa Co. Ltd. (Permit
number: BP-2013–0008). All efforts were made to minimize
suffering. Total RNA was extracted from frozen tissues with TRI
Reagent (Molecular Research Center Inc., Cincinnati, OH, USA)
according to the manufacturer’s instructions. First-strand cDNAs
were prepared by incubating total RNA with a random hexamer
and mouse mammary tumor virus reverse transcriptase (Promega
Corp., Madison, WI, USA) at 37uC for 1 h. Xenopus cDNAs were
obtained as previously described [43]. To clone full-length open-
reading frame cDNAs for GCRPRs, gene-specific primers were
designed based on the predicted sequences retrieved from the
Ensembl Genome Database. PCR conditions were as follows:
denaturation at 95uC for 5 min, followed by different cycles at
95uC for 1 min, 58uC for 1 min, and 72uC for 1 min.
Plasmid Constructs
The pcDNA3.1 expression vector was purchased from Invitro-
gen Corp. (San Diego, CA, USA). The CRE-luc vector, which
contains four copies of the cyclic AMP-responsive element (CRE;
TGACGTCA), was purchased from Stratagene (La Jolla, CA,
USA). The cDNA for huGIPR was kindly provided by Dr.
Bernard Thorens (Institute of Pharmacology and Toxicology,
Switzerland). The cDNAs for huGLP2R and huGCGR were from
BRN SCIENCE Inc. (Seoul, Korea). The cDNA for medaka
GCRPR was synthesized by GenScript (Piscataway, NJ, USA).
The cDNAs for chGCRPR and xeGCRPR were obtained by RT-
PCR from chicken and Xenopus tissues. All genes were constructed
at the EcoRI and XhoI sites of pcDNA3.1 by PCR using
appropriate primers from CosmogenTech Inc. (Seoul, Korea).
The identity of each gene was verified by sequencing.
Chimeric forms of chGCRPR and GLP1R were generated by
standardoverlap-extensionPCRwithanappropriateprimerset [27].
The N-terminal extracellular region covering 145 amino acids of
chGCRPR was fused with the core domain of chGLP1R or
huGLP1R ranging from the first transmembrane region (starting
from amino acid position 144 for chGLP1R and position 148 for
huGLP1R) to theC-terminal intracellular region.Thechimeric gene
was inserted into the EcoRI and XhoI sites of pcDNA3.1.
Cell Transfection and Luciferase Assay
HEK293T cells (American Type Culture Collection, Manassas,
VA, USA) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum,
100 U/ml penicillin G, and 100 mg/ml streptomycin (Invitrogen).
Cells were seeded in 48-well plates at a density of 1.46104 cells per
well 1 day before transfection. A mixture containing 75 ng of
pGL3-CRE-luciferase reporter construct, 75 ng of expression
plasmid, and 2 ml of Effectene reagent (Qiagen, Chatsworth, CA,
USA) was prepared and added to each well according to the
manufacturer’s instructions. Approximately 48 h after transfec-
tion, cells were treated with the respective ligands for 6 h. Cells
were lysed by adding 100 ml lysis buffer and the luciferase activity
in 40 ml of cell extract was determined on a luciferase assay system
according to the standard protocol for the Synergy 2 Multi-Mode
Microplate Reader (BioTek, Winooski, VT, USA).
Measurement of Inositol Phosphate Production
An IP production assay was performed as described previously
[53]. HEK293T cells were seeded into a 12-well plate and
transfected with the chGCRPR, xeGCRPR, or mdGCRPR
plasmid. After transfection, cells were incubated in M199 medium
(Invitrogen) in the presence of 1 mCi/ml myo-[3H] inositol
(Amersham Biosciences, Piscataway, NJ, USA)/well for 20 h.
Media were removed, and cells were washed with 0.5 ml Buffer A
(140 mM NaCl, 20 mM HEPES, 4 mM KCl, 8 mM D-glucose,
Table 5. Ligand potency (EC50 value) and efficacy (Emax value) for GCRPR, GLP1R, and chimeric receptors.
chGCRPR chGLP1R chimeric chGCRPR/chGLP1R chimeric chGCRPR/huGLP1R
peptides EC50 Emax EC50 Emax EC50 Emax EC50 Emax
[nM]
[fold
induction] [nM]
[fold
induction] [nM]
[fold
induction] [nM]
[fold
induction]
chGCRP 0.3260.06 5.5660.09 8.0360.60 19.1660.19 8.5760.87 7.3060.09 9.4461.31 62.8861.27
chGLP1 18.2861.76a 5.8060.07 0.2060.03a 28.2360.39a 1.5260.13a 12.6460.13a 2.2960.44a 91.9462.18a
[GQA]GCRP 0.2860.05b 5.6060.09 0.9460.13a 18.9960.30b 0.6360.06a 7.1860.07b 0.8660.14a 60.6261.15b
[KMK]GLP1 1.0260.19b 5.7760.10 0.5060.06a 28.3860.39a 1.7160.14a 12.7760.12a 3.2560.48a 91.1561.65a
Results are presented as mean 6 S.E. of at least three independent experiments. a, P,0.05 vs. chGCRP; b, P,0.05 vs. chGLP1.
doi:10.1371/journal.pone.0065420.t005
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1 mM MgCl2, 1 mM CaCl2, and 1 mg/ml fatty acid-free bovine
serum albumin). Cells were then preincubated for 30 min with
Buffer A containing 10 mM LiCl. The reaction was terminated by
replacing incubation media with 0.5 ml ice-cold 10 mM formic
acid. After 30 min at 4uC, formic acid extracts were transferred to
columns containing Dowex anion-exchange resin (AG-1-X8 resin,
Bio-Rad). Total IPs were then eluted with 1 ml ammonium
formate and 0.1 M formic acid. Radioactivity was measured on a
Tri-Carb 3100TR scintillation counter (PerkinElmer Life Scienc-
es, Waltham, MA, USA).
Binding Assay
chGCRP was radioiodinated by the chloramine-T method and
then purified by chromatography on a Sephadex G-25 column
(Sigma-Aldrich) in 0.01 M acetic acid and 0.1% BSA [27].
HEK293T cells were transfected with GCRPR (300 ng of DNA/
well in 12-well plates) with Effectene (Qiagen). Cells were washed
after 48 h and incubated for one additional hour with binding
buffer (serum-free DMEM with 0.1% BSA, pH 7.4) containing
100,000 cpm 125I-labeled ligand in the absence or presence of
various concentrations of cold peptides. Cells were washed twice
with ice-cold Dulbecco’s PBS and dissolved in 1% SDS and 0.2 M
NaOH. Radioactivity was measured with the Wallac 1489 Wizard
3 c-counter (PerkinElmer Life Science).
cAMP Accumulation
GCRP-induced cAMP mobilization was measured in
HEK293T cells that stably express the pGlosensorTM-22F cAMP
plasmid (Promega Corp., Madison, WI, USA). Glosensor-22F
cAMP HEK293T cells were seeded into 96-well plates 24 h before
transfection. After 48 h, Glosensor cAMP substrates were added to
cells in CO2-independent media. After 2 h, cells were stimulated,
and luminescence was measured for up to 30 min at 26uC in a
microplate reader.
Data Analysis
Data analysis was performed by nonlinear regression with a
sigmoidal dose-response. The agonist concentrations that induced
half-maximal stimulation (EC50) or half-maximal inhibition of
binding (IC50) were calculated with GraphPad PRISM4 software
(GraphPad Software Inc., San Diego, CA, USA). All data were
presented as mean 6 S.E. of at least three independent
experiments. Group means were compared by Student’s t test or
one-way analysis of variance followed by Bonferroni’s multiple
comparison tests. p,0.05 was accepted as significant.
Supporting Information
Figure S1 Synteny for the GCRP family gene-containing
chromosomes of vertebrates. A, The genomic locations of
the GCRP gene and its neighboring genes were compared with
those of their orthologous genes in vertebrates, including human,
anole, chicken, Xenopus, zebrafish, medaka, tetraodon, and
stickleback. Orthologous genes are aligned in the same column.
Chromosome numbers are labeled above the indicated gene.
Chromosomal locations (megabases) are shown beneath the gene.
The genome scaffold numbers for Xenopus started with the same
GL17 followed by four variable digits. Only the variable numbers
are shown above the gene. For example, if a scaffold number for
Xenopus GCRP is GL172703, only 2703 is written above the gene in
the figure. Similarly, the last four digits of the genome scaffold
numbers for anole are shown. If fish genes were doubled due to
teleost-specific genome duplication, the chromosome numbers and
gene locations of the doubled genes are indicated in two lines with
different colors. The absence of the peptide genes is indicated by
white boxes with broken lines, below which ‘x’ is labeled. B, Four
putative early paralogons containing the GCRP family peptide
gene with their neighboring genes. Human chromosome numbers
are above the indicated gene, and the gene locations (megabase)
are shown beneath the gene. Paralogs of each gene in different
paralogons were aligned on the same column with the same colors.
The positions of each gene block in the gnathostome ancestor
chromosome (GAC) in the N-models are indicated in the left.
(PDF)
Figure S2 Synteny for the chromosomal locations of
GCRPR family genes in vertebrates. A, The genome
locations of GCRPR, GCGR, GLP2R, GLP1R, GIPR, and their
neighboring genes in vertebrates, including human, anole,
chicken, Xenopus, zebrafish, medaka, tetraodon, and stickleback
are shown. Orthologous genes are aligned on the same column.
Chromosome numbers are shown above the indicated gene, and
the gene locations (megabase) are shown beneath the gene. The
absence of the receptor genes is indicated by white boxes with
broken lines, below which ‘x’ is labeled. The positions of each gene
block in the gnathostome ancestor chromosome (GAC) in the N-
models are indicated at the top of the column. B, Local
duplication of GCGR, GLP2R, GCGPR, and GLP1R after two
rounds of whole genome duplication. GIPR and its neighboring
genes are aligned on human chromosome 19 of GAC G2.
Although GCGR, CCRPR, GLP2R, and GLP1R are on different
GAC blocks, they are aligned on one paralogon based on synteny
with GIPR-containing paralogon. Two additional paralogons
missing GCGR family members were identified by synteny
analyses. Human chromosome numbers are shown above the
indicated gene, and the gene locations (megabase) are shown
beneath the gene. Ohnologs of each gene on different paralogons
were aligned on the same column with the same colors and
connected by straight lines. Paralogs were connected by a dashed
line. Local duplications were indicated by curved lines.
(PDF)
Information S1
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